Briggs Morrison
CIK 1654430 · President, Head of R&D · last filed 2026-06-26
Briggs Morrison is a President, Head of R&D who has filed 64 SEC Form 4 insider transactions across 8 companies since 2017. The most recent filing, for ARVN, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$27.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SNDX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
400 TOTTEN POND ROAD, SUITE 110
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARVN | Director | 111,548 | $7.45 | $831.0K | -$2.18M | 14 | 2026-06-26 |
| CRSP | Director | — | $51.47 | — | $0 | 2 | 2026-06-09 |
| HOWL | Director | — | $1.04 | — | $0 | 5 | 2025-06-13 |
| Carisma Therapeutics Inc. (CARM) Delisted | Director | — | $0.00 | — | $0 | 2 | 2024-06-27 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 4,800 | $2.65 | $12.7K | $96.0K | 5 | 2024-06-20 |
| SNDX | Director | 34,836 | $13.69 | $476.9K | -$25.70M | 27 | 2024-02-09 |
| Codiak BioSciences, Inc. (CDAK) Delisted | Director | 4,761 | $0.06 | $271 | $100.0K | 2 | 2021-02-17 |
| NXTC | Director | — | $5.71 | — | $0 | 2 | 2020-06-15 |
Recent Filings
64 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | ARVN | Grant (A) | +15,527 | $0 | EDGAR |
| 2026-06-09 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2026-03-09 | ARVN | Buy (P) | +20,000 | $268.1K | EDGAR |
| 2025-09-24 | ARVN | Buy (P) | +30,000 | $227.0K | EDGAR |
| 2025-06-27 | ARVN | Grant (A) | +16,025 | $0 | EDGAR |
| 2025-06-13 | HOWL | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2024-06-27 | Carisma Therapeutics Inc. (CARM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-20 | Repare Therapeutics Inc. (RPTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-31 | ARVN | Grant (A) | +5,899 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.